Neurorehabilitation medical device company Mobia Medical (MOBI.US), based in Austin, Texas, has submitted an application for an initial public offering to the U.S. Securities and Exchange Commission (SEC). The company plans to list on the Nasdaq Global Market under the ticker symbol "MOBI," aiming to raise up to $100 million. Bank of America Securities, J.P. Morgan, and Goldman Sachs are serving as joint book-running managers for the offering, though specific pricing terms have not yet been disclosed.

Mobia Medical is a commercial-stage medical device company whose core product is the Vivistim Vagus Nerve Stimulation System. This system is the first and only FDA-approved implantable solution designed specifically to improve upper limb mobility in chronic ischemic stroke survivors. By delivering targeted electrical stimulation during functional movement training, the Vivistim system leverages neuroplasticity to help rebuild neural connections and significantly enhance hand and arm motor function.

According to management estimates, there are over 4 million chronic ischemic stroke survivors globally, with approximately 1 million possessing the health status, cognitive ability, and motivation to participate in post-stroke rehabilitation. Based on the system's pricing, this represents a market opportunity valued at $30 billion.

Founded in 2007 and headquartered in Austin, Texas, Mobia Medical reported revenue of $32 million for the twelve months ended December 31, 2025, more than doubling its revenue of $15.6 million from the 2024 fiscal year.